Target and Its Patented Drug(s)
| Target General Information | Top | ||||
|---|---|---|---|---|---|
| Target ID | T65501 | Target Info | |||
| Target Name | DNA [cytosine-5]-methyltransferase 3B (DNMT3B) | ||||
| Synonyms | M.HsaIIIB; Dnmt3b; DNA methyltransferase HsaIIIB; DNA methyltransferase 3B; DNA MTase HsaIIIB; DNA (cytosine-5)-methyltransferase 3B | ||||
| Target Type | Clinical trial Target | ||||
| Gene Name | DNMT3B | ||||
| Biochemical Class | Methyltransferase | ||||
| UniProt ID | |||||
| Patent(s) and the Corresponding Patented Drug(s) | Top | ||||
|---|---|---|---|---|---|
| World Intellectual Property Organization (WIPO) | |||||
| Patent ID | WO2014011573 | ||||
| Title | Oligonucleotide Inhibitors of Dna Methyltransferases and Their Use In Treating Diseases. | ||||
| Abstract | Modified oligonucleotides comprising CpG sites, wherein the cytosine is replaced by cytosine analogs are provided as well as methods of making the oligonucleotides and their use in inhibiting DNA Methyltransferase, inhibiting or reversing methylation of genes and in treating cancer, tumorigenesis and hyper-proliferative disorders. | ||||
| Applicant(s) | Metheor Therapeutics Corporation | ||||
| Representative Drug(s) | D0HA0J | Drug Info | IC50 = 295 nM | Click to Show More | [1] |
| 2 | D0W9VZ | Drug Info | IC50 = 363 nM | [1] | |
| 3 | D0QY0N | Drug Info | IC50 = 1430 nM | [1] | |
| 4 | D02WRM | Drug Info | IC50 = 1940 nM | [1] | |
| Patent ID | WO2013062945 | ||||
| Title | Chemical Compounds. | ||||
| Abstract | The invention is directed to substituted heteroaryl derivatives. Specifically, the invention is directed to compounds according to Formula Q: wherein D, L, M, W, X, Y, and Z are defined herein. The compounds of the invention are inhibitors of DNA methyltransferase (DNMT) activity - including DNMT1, DNMT3a, or DNMT3b - and are useful in the treatment of cancer and hyperproliferative diseases. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention. | ||||
| Applicant(s) | Glaxosmithkline Intellectual Property (No.2) Limited | ||||
| References | Top | ||||
|---|---|---|---|---|---|
| REF 1 | DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.